Suppr超能文献

大鼠简易、快速且可靠的鞘内导管插入法的开发。

Development of a simple, rapid, and robust intrathecal catheterization method in the rat.

作者信息

Mazur Curt, Fitzsimmons Bethany, Kamme Fredrik, Nichols Brandon, Powers Berit, Wancewicz Ed

机构信息

Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010, USA.

出版信息

J Neurosci Methods. 2017 Mar 15;280:36-46. doi: 10.1016/j.jneumeth.2017.02.001. Epub 2017 Feb 2.

Abstract

BACKGROUND

The blood brain barrier (BBB) is an impediment to the development of large and highly charged molecules as therapeutics for diseases and injuries of the central nervous system (CNS). Antisense oligonucleotides (ASOs) are large (6000-8000MW) and highly charged and therefore do not cross the BBB. A method of circumventing the blood brain barrier to test ASOs, and other non-BBB penetrant molecules, as CNS therapeutics is the direct administration of these molecules to the CNS tissue or cerebral spinal fluid.

NEW METHOD

We developed a rapid, simple and robust method for the intrathecal catheterization of rats to test putatively therapeutic antisense oligonucleotides. This method utilizes 23-gauge needles, simply constructed ½in. long 19-gauge guide cannulas and 8cm long plastic PE-10 sized catheters.

COMPARISON WITH EXISTING METHODS

Unlike the cisterna magna approach, this method uses a lumbar approach for intrathecal catheterization with the catheter residing entirely in the cauda equina space minimizing spinal cord compression. Readily available materials and only a few specialized pieces of equipment, which are easily manufactured, are used for this intrathecal catheterization method.

CONCLUSIONS

This method is easy to learn and has been taught to multiple in house surgeons, collaborators and contract laboratories. Greater than 90% catheterization success is routinely achieved with this method and as many as 100 catheters can be placed and test substance administered in one 6-h period. This method has allowed the pre-clinical testing of hundreds of ASOs as therapeutics for CNS indications.

摘要

背景

血脑屏障(BBB)阻碍了大分子和高电荷分子作为中枢神经系统(CNS)疾病和损伤治疗药物的开发。反义寡核苷酸(ASO)分子量大(6000 - 8000MW)且电荷高,因此无法穿过血脑屏障。一种绕过血脑屏障来测试ASO及其他非血脑屏障穿透性分子作为中枢神经系统治疗药物的方法是将这些分子直接注入中枢神经系统组织或脑脊液。

新方法

我们开发了一种快速、简单且可靠的大鼠鞘内导管插入术方法,用于测试潜在治疗性反义寡核苷酸。该方法使用23号针头、构造简单的半英寸长19号引导套管和8厘米长的塑料PE - 10规格导管。

与现有方法的比较

与小脑延髓池穿刺法不同,该方法采用腰部穿刺进行鞘内导管插入,导管完全位于马尾间隙,可将脊髓压迫降至最低。这种鞘内导管插入术方法使用的是现成材料,仅需少量易于制造的专业设备。

结论

该方法易于学习,已传授给多位内部外科医生、合作者和合同实验室。使用此方法通常能实现超过90%的导管插入成功率,在一个6小时时间段内可放置多达100根导管并注入测试物质。该方法已使数百种ASO作为中枢神经系统适应症治疗药物的临床前测试成为可能。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验